文献速递外周动脉疾病

水化可能逆转大多数下肢间歇性跛行或静息痛症状

Hydration may reverse most symptoms of lower extremity intermittent claudication or rest pain.
PubMed 文献 · J Vasc Surg · 2020-01-01

本研究纳入132例经危险因素控制、监督下运动和西洛他唑治疗未改善的严重间歇性跛行或静息痛患者,给予水化(每日饮水至少2000 mL)及口服白蛋白补充。131例依从患者6个月后踝肱指数从0.6改善至0.75,跛行距离从100米增至535米,皮肤温度升高,所有依从患者缺血相关状态改善。

要点

  • 每日饮水至少2000 mL并口服白蛋白使血清白蛋白达4 g/dL,可改善跛行距离和踝肱指数。
  • 131例依从患者6个月后踝肱指数从0.6升至0.75,跛行距离从100米增至535米。
  • 不依从患者症状、皮肤温度、踝肱指数及跛行时间距离均无变化。

核心结论

  • 适当水化(每日饮水至少2000 mL)联合口服白蛋白补充使血清白蛋白达4 g/dL,可能改善因外周动脉疾病导致的致残性跛行或静息痛。

研究设计与样本

  • 单中心前瞻性研究,纳入132例严重间歇性跛行或静息痛患者,所有患者接受水化治疗并鼓励行走但非监督下行走。

主要发现

  • 131例依从患者6个月后踝肱指数从0.6改善至0.75(P < .0001),足部皮肤温度从29.4°C升至31.7°C(P = .009)。
  • 6周时平板运动跛行距离从100米增至535米(P < .0001),65.83%患者6个月时保持稳定。
  • 34.17%患者跛行距离进一步增加200(100-500)米,跛行时间从1.3分钟延长至6.3分钟(P < .0001)。
  • 唯一不依从患者症状、皮肤温度、踝肱指数及跛行时间距离均无变化。

关键数值与推荐

  • 水化定义为24小时内饮水至少2000 mL并持续6个月。
  • 口服白蛋白补充(蛋清或白蛋白粉)每日0.6 g/kg,使血清白蛋白达4 g/dL。
  • 每日总盐摄入3.5 g。

临床怎么用

  • 对于经危险因素控制、监督下运动和西洛他唑治疗仍未改善的严重跛行或静息痛患者,可考虑将适当水化联合口服白蛋白补充纳入治疗手段。

局限性

  • 研究为非对照设计,样本量有限,需进一步比较研究评估水化和提高血清胶体渗透压的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medical treatment of severe intermittent claudication or critical limb-threatening ischemia causing rest pain frequently achieves only partial relief or is not effective at all. METHODS: Patients with severe intermittent claudication or rest pain of the lower extremities who did not improve after control of risk factors, supervised exercises, and cilostazol medication were included in this study. All patients were treated with hydration. They were asked to drink 2500 mL of fluids (water, soup, milk) during a 24-hour period and to ingest 0.6 g/kg of albumin a day, as egg white or albumin powder. Total salt administered daily was 3.5 g. Symptoms, skin temperature, ankle-brachial index, albumin concentration in serum, and time and distance to claudication were recorded before treatment, at 6 weeks, and at 6 months. Electrolytes were measured monthly. No additional treatment was used during the study. Walking was encouraged but not supervised. The trial has continued indefinitely. For statistical analysis, SPSS software (IBM Corp, Armonk, NY) was used. The Ethical Committee approved the protocol, and an informed consent was signed by all patients. RESULTS: There were 132 patients (94 male, 38 female) included in the study. Median age was 72.5 years (range, 67-77 years); all had severe claudication of a mean of 100 meters or rest pain. Symptoms had been present for >5 months in all patients; 22 (16.8%) had rest pain. Proper hydration, determined as drinking at least 2000 mL of water during 24 hours for a period of 6 months, was achieved in 131 compliant patients. Only one patient failed to drink 2000 mL of water or more. Ankle-brachial index in 131 compliant patients improved from 0.6 to 0.75 (P < .0001) after 6 months. Skin temperature of the feet increased from 29.4°C to 31.7°C (P = .009). Distance to claudication using the treadmill improved from 100 meters to 535 meters (P < .0001) at 6 weeks and remained stable at 6 month in 65.83% of the patients; in 34.17% of them, distance to claudication increased further by 200 (100-500) meters and time to claudication improved from 1.3 to 6.3 minutes (P < .0001) at 6 weeks, but the same group of patients (34.17%) that increased the distance to claudication further prolonged the time to claudication by 2.49 (1.24-6.23) minutes. All 131 compliant patients improved their status related to lower extremity ischemia; the noncompliant patient did not have any variation of symptoms, skin temperature, ankle-brachial index, or time and distance to claudication. All patients survived the initial 6 months of treatment; afterward, three patients abandoned the treatment and four died of unrelated causes. After the 6-month control, 49% of the patients continued to improve the time and distance to claudication as well as the ankle-brachial index. The rest of the patients conserved the initial improvement. Five patients who had significantly improved the time and distance to claudication were asked to decrease water intake for 3 days. No changes in time and distance to claudication were detected. Hydration was reinitiated. CONCLUSIONS: This study suggests that proper hydration by drinking ≥2000 mL of water daily and albumin complement orally to reach 4 g/dL in serum could be included in the armamentarium of physicians treating patients with disabling claudication or rest pain caused by peripheral artery disease. Further comparative studies to assess the benefit of hydration and increasing the serum oncotic pressure are warranted.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Parodi JC, Fernandez S, Moscovich F, et al. Hydration may reverse most symptoms of lower extremity intermittent claudication or rest pain. J Vasc Surg. 2020. PMID: 32972591. doi:10.1016/j.jvs.2020.05.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。